The discovery of antimicrobial chemotherapeutics
|
|
- Megan Watson
- 5 years ago
- Views:
Transcription
1 58 Commentary Volume 8 No. 1, 2011 COMMENTARY Bacterial Resistance to Antibiotics: A Growing Public Health Problem Justin Dhat-Ming Tilak, BSc (Hons) THE EMERGENCE OF CLINICAL ANTIMICROBIAL RESISTANCE The discovery of antimicrobial chemotherapeutics and their introduction into the clinical setting ranks among the most significant advances in the history of medicine. 1 Infectious disease is no longer the leading cause of death in the industrialized world, due in large part to the effectiveness of antimicrobial drugs. 2,3 The rapid and widespread emergence of clinical antibiotic resistance among bacterial pathogens, however, presents a formidable challenge to infectious disease management. 4 Antibiotic-resistant bacterial strains are prevalent around the globe, 4 including Canada. 5 The development of these strains has been identified as a serious public health issue, particularly in hospital settings. 6 Noteworthy antibiotic-resistant pathogens found in Canadian hospitals include methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), β-lactam- and fluoroquinolone-resistant Enterobacteriaceae (e.g. Escherichia coli and Klebsiella pneumoniae), and multidrug-resistant gram-negative bacilli (e.g. Pseudomonas aeruginosa), among others (Table 1). 6-8 Although lower than those observed in the United States, antibiotic resistance rates in Canada have increased dramatically in recent years. In 2008, MRSA accounted for 27.0% of all Staphylococcus aureus isolates in Canadian hospitals, 8 rising from 6.0% in Similarly, 21.4% of Escherichia coli urinary tract isolates were resistant to the fluoroquinolone ciprofloxacin, 8 up from 1.1% in Rates of multidrug resistance are also high, particularly in intensive care units. 11 From , 12.6% of Pseudomonas aeruginosa isolates from Canadian intensive care units demonstrated resistance to three or more antibiotic classes. 11 KEY POINTS The prevalence of antibiotic resistance among bacterial pathogens in Canada continues to rise. The mechanisms of bacterial antibiotic resistance are numerous and diverse. Clinical resistance has been observed to nearly all available antibiotics. Infections due to antibiotic-resistant bacteria frequently result in adverse clinical outcomes and increased healthcare costs. The continued effectiveness of antimicrobial chemotherapy depends on increased awareness of the consequences of antimicrobial resistance, effective strategies to prevent the emergence and spread of resistant organisms, as well as the development of new antimicrobial compounds. Table 1. Bacterial Pathogens Demonstrating Significant Levels of Antibiotic Resistance in Canadian Hospitals 6-8 Classification Species Gram-positive Enterococcus faecalis Enterococcus faecium Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Gram-negative Acinetobacter baumannii Enterobacter cloacae Escherichia coli Klebsiella pneumoniae Pseudomonas aeruginosa THE DIVERSITY OF MECHANISMS CONFERRING ANTIBIOTIC RESISTANCE The mechanisms of bacterial antibiotic resistance are numerous and diverse, and the clinical resilience of many pathogens is attributable to their expression of several of these mechanisms. 12 All species possess some degree of intrinsic antibiotic resistance, and exposure to a certain drug
2 MUMJ Commentary 59 then provides selective pressures to promote the emergence of acquired resistance through mutation or horizontal gene transfer. No antibiotic is immune to bacterial resistance, as evidenced by the discovery of resistance to nearly every clinically-available antibiotic (Table 2). 12,14 Table 2. Major Antibiotics, Targets, and Associated Resistance Mechanisms 12,14 Antibiotic Class Aminoglycosides Amikacin Gentamicin β-lactams Penicillins Cephalosporins Carbapenems Monobactams Example Agents Bacterial Target Amoxicillin Cloxacillin Cefazolin Ceftazidime Meropenem Aztreonam Fluoroquinolones Ciprofloxacin Levofloxacin Resistance Mechanisms Protein synthesis Enzymatic Cell wall synthesis Enzymatic Decreased uptake Active efflux DNA synthesis Glycopeptides Vancomycin Cell wall synthesis Glycylcyclines Tigecycline Protein synthesis Lincosamides Clindamycin Protein synthesis Lipopeptides Daptomycin Cell membrane Macrolides Azithromycin Clarithromycin Protein synthesis Nitroimidazoles Metronidazole DNA synthesis Unclear Oxazolidinones Linezolid Protein synthesis Phenicols Chloramphenicol Protein synthesis Enzymatic Polymyxins Colistin Cell membrane Unclear Pyrimidines Trimethoprim Folate metabolism Rifamycins Rifampin RNA synthesis Streptogramins Quinupristin Dalfopristin Protein synthesis Enzymatic Active efflux Sulfonamides Sulfamethoxazole Folate metabolism Tetracyclines Doxycycline Tetracycline Protein synthesis The production of antibiotic-inactivating enzymes is one of the best known mechanisms of resistance, 15 and is typified by the β-lactamases. 16 A major group of β-lactamases is the extended-spectrum β-lactamases (ESBLs), which inactivate many penicillins, cephalosporins, and monobactams, but generally not carbapenems. 17 Additionally, plasmids encoding ESBLs often contain genes encoding resistance to other antibiotic classes, namely aminoglycosides 18 and fluoroquinolones, 19 and thus are significant contributors to multidrug resistance. 20 The rising prevalence of ESBLs among the Enterobacteriaceae has forced a greater reliance on the use of carbapenems. 21 Yet this treatment option is also threatened by pathogen acquisition of carbapenem-inactivating enzymes. 22 Among the notable carbapenemases is the recently discovered (and widely publicized) New Delhi metallo-β-lactamase-1 (NDM-1), which has been identified in Escherichia coli and Klebsiella pneumoniae. 23 NDM-1-carrying strains have now been isolated in many countries, 24 including Canada. 25 In addition to β-lactam resistance, enzymatic also plays a major role in resistance to aminoglycosides. 26 Other mechanisms of resistance include decreased uptake and increased active efflux, both of which prevent the accumulation of the antibiotic at the target site. 27 In gram-negative bacteria, resistance to certain β-lactams is mediated through decreases in porin production, 28,29 as β-lactams must cross the outer cell membrane through porins in order to reach their target: penicillin-binding proteins. 30 Active efflux involves the energy-dependent removal of antibiotics from the cell by efflux pumps. 27 Although first described as a mechanism of tetracycline resistance in Escherichia coli, 31 class-specific and multidrug efflux systems conferring resistance to most antibiotic classes have now been characterized in many bacterial pathogens. 32 Multidrug efflux pumps are major contributors to antibiotic resistance in gram-negative bacilli, including Acinetobacter baumannii 33 and Pseudomonas aeruginosa. 34 The alteration of target sites to prevent the binding of antibiotics is another mechanism of resistance. 35 A clinicallysignificant example is MRSA, in which the production of an altered penicillin-binding protein with decreased affinity for methicillin confers resistance to nearly all β-lactams, including those resistant to by most staphylococcal β-lactamases (e.g. methicillin, oxacillin, cloxacillin). 36,37 Modified penicillin-binding proteins also account for β-lactam resistance in other gram-positive bacteria. 38,39 Other notable examples of target site alteration include fluoroquinolone resistance in various species, macrolide resistance in Streptococcus pneumoniae, 43 and vancomycin resistance in VRE. 44 THE CLINICAL AND ECONOMIC IMPACT OF ANTIBIOTIC RESISTANCE Antibiotic resistance among bacterial pathogens has major clinical implications for infectious disease treatment. The spread of resistant organisms in the clinical setting presents a
3 60 Commentary Volume 8 No. 1, 2011 considerable public health concern, as infections with such organisms are often associated with poor clinical outcomes. 45,46 Patients infected with resistant organisms frequently require lengthier hospitalizations and suffer higher mortality rates, particularly in the case of bloodstream infections caused by MRSA, 47 VRE, 48 and ESBL-producing Enterobacteriaceae. 49,50 The adverse clinical outcomes associated with resistant infections are due in large part to limitations in therapeutic options, as well as decreased efficacy of remaining antibiotic options (i.e. vancomycin). Resistance frequently compromises the effectiveness of empirically-determined treatments, resulting in increased rates of treatment failure Failure of first-line therapies may necessitate further investigations, additional antibiotic treatments, surgical procedures, or may result in patient death. 45 The management of resistant infections is further complicated by the fact that antibiotics used to treat resistant infections are often associated with more severe toxicities. 53 One example is colistin, a treatment of last resort for infections caused by multidrug-resistant gram-negative bacilli, which has known nephrotoxicity. 54 However, colistin use continues due to a desperate need for effective antibiotics against gram-negative bacilli. 55,56 Research trends in antimicrobial development compound the issue of limited treatment options, as the development of new antimicrobial agents continues to decline. 57 The dwindling number of chemotherapeutic options, particularly in the case of multidrug-resistant pathogens, highlights the unsettling possibility that infections refractory to all available treatments may soon arise in the clinic. 58,59 Not only does antibiotic resistance negatively impact clinical outcomes, but it is also associated with increased healthcare costs. 46,53 These costs are due to prolonged patient hospitalizations, delayed recoveries, and the need to implement infection control initiatives aimed at preventing the spread of resistant organisms. In 2002, the direct hospitalization costs incurred in Canada as a result of antibiotic-resistant bacterial infections were estimated at between CDN $14 and $26 million, a notable CDN $9 to $14 million more than it would have cost had those infections been susceptible to traditional antibiotic therapies. 60 Patient screening for resistant organisms and precautions to prevent their spread were estimated to have cost an additional CDN $26 million. 60 This estimate does not include the cost of treating resistant infections that occur outside of hospitals. 60 Purchasing new and advanced antimicrobial drugs also presents a substantial financial strain to the healthcare system. In the case of Staphylococcus aureus, treatments for methicillin-resistant strains are significantly more expensive than those for methicillinsensitive strains (Table 3). 61 Table 3. The Cost of Antibiotics for the Treatment of Staphylococcus Aureus in Pathogen Antibiotic Daily Cost (CDN) MSSA Cloxacillin $0.70-$14.40 MRSA Vancomycin $92.54 Linezolid $ Daptomycin Tigecycline $ $ MSSA methicillin-sensitive Staphylococcus aureus; MRSA methicillin-resistant Staphylococcus aureus. CONCLUDING REMARKS The issue of antimicrobial resistance is an escalating challenge to public health. Antimicrobial drugs are among the most revolutionary pharmaceuticals in modern medicine, but the emergence of resistance among bacterial pathogens continues to compromise their clinical effectiveness. Antibioticresistant infections are associated with increased patient morbidity and mortality, as well as increased healthcare costs. The need for increased awareness of antimicrobial resistance and its consequences has led to its selection by the World Health Organization as the theme for World Health Day Although there are unique trends in antimicrobial resistance in Canada, it is truly a global health problem. 63 While the focus of this article has been limited to bacterial antibiotic resistance, the worldwide existence and impact of antimicrobial resistance among viral, 64 fungal, 65 and parasitic (including protozoal 66 and helminthic 67 ) pathogens should not be overlooked. Controlling antimicrobial resistance requires a multifaceted approach. The selective pressures of antimicrobial exposure emphasize the need for caution and stewardship in antimicrobial prescription, 68 while the increasing prevalence of resistant organisms in hospitals underscores the need for surveillance of resistance rates and implementation of strong infection control practices. 69 The lack of viable treatment options for multidrug-resistant organisms also stresses the need for the continued development of novel antimicrobial compounds. 70 Such initiatives will ensure antimicrobial chemotherapy will continue to fulfill its essential role in infectious disease treatment in the future.
4 MUMJ Commentary 61 REFERENCES 1. Bud R. Medical Milestones Antibiotics: The epitome of a wonder drug. BMJ 2007; 334: S6. 2. Cohen ML. Changing patterns of infectious disease. Nature 2000; 406: Armstrong GL, Conn LA, Pinner RW. Trends in infectious disease mortality in the United States during the 20th century. JAMA 1999; 281: Levy SB & Marshall B. Antibacterial resistance worldwide: Causes, challenges and responses. Nat Med 2004; 10: S122-S Conly J. Antimicrobial resistance in Canada. CMAJ 2002; 167: Mulvey MR & Simor AE. Antimicrobial resistance in hospitals: How concerned should we be? CMAJ 2009; 180: Zhanel GG, Karlowsky JA, DeCorby M, et al. Prevalence of antimicrobial-resistant pathogens in Canadian hospitals: Results of the Canadian Ward Surveillance Study (CANWARD 2007). Can J Infect Dis Med Microbiol 2009; 20: 9A-19A. 8. Zhanel GG, DeCorby M, Adam H, et al. Prevalence of antimicrobial-resistant pathogens in Canadian hospitals: Results of the Canadian Ward Surveillance Study (CANWARD 2008). Antimicrob Agents Chemother 2010; 54: Simor AE, Ofner-Agostini M, Bryce E et al. The evolution of methicillin-resistant Staphylococcus aureus in Canadian hospitals: 5 years of national surveillance. CMAJ 2001; 165: Jones RN, Kugler KC, Pfaller MA, et al. Characteristics of pathogens causing urinary tract infections in hospitals in North America: Results from the SENTRY Antimicrobial Surveillance Program, Diagn Microbiol Infect Dis 1999; 35: Zhanel GG, DeCorby M, Laing N, et al. Antimicrobial-resistant pathogens in intensive care units in Canada: Results of the Canadian National Intensive Care Unit (CAN-ICU) study, Antimicrob Agents Chemother 2008; 52: Alekshun MN & Levy SB. Molecular mechanisms of antibacterial multidrug resistance. Cell 2007; 128: Normark BH & Normark S. Evolution and spread of antibiotic resistance. J Intern Med 2002; 252: Archer GL & Polk RE. Treatment and prophylaxis of bacterial infections. In: Fauci AS, Braunwald E, Kasper DL et al. (eds). Harrison s Principles of Internal Medicine. 17th ed. New York: McGraw-Hill; 2008; Wright GD. Bacterial resistance to antibiotics: Enzymatic degradation and. Adv Drug Deliv Rev 2005; 57: Bush K & Jacoby GA. Updated functional classification of β-lactamases. Antimicrob Agents Chemother 2010; 54: Paterson DL & Bonomo RA. Extended-spectrum β-lactamases: A clinical update. Clin Microbiol Rev 2005; 18: Galani I, Xirouchaki E, Kanellakopoulou, et al. Transferable plasmid mediating resistance to multiple antimicrobial agents in Klebsiella pneumoniae isolates in Greece. Clin Microbiol Infect 2002; 8: Robicsek A, Jacoby GA, Hooper DC. The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect Dis 2006; 6: Giamarellou K. Multidrug resistance in gram-negative bacteria that produce extended-spectrum β-lactamases (ESBLs). Clin Microbiol Infect 2005; 11: S1-S Pitout JDD & Laupland KB. Extended-spectrum β-lactamases-producing Enterobacteriaceae: An emerging public-health concern. Lancet Infect Dis 2008; 8: Toye B, Krajden S, Fuksa M, et al. Carbapenem resistance in Canada. CMAJ 2009; 180: Kumarasamy KK, Toleman MA, Walsh TR, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: A molecular, biological, and epidemiological study. Lancet Infect Dis 2010; 10: Pillai DR, McGeer A, Low DE. New Delhi metallo-β-lactamase-1 in Enterobacteriaceae: Emerging resistance. CMAJ 2011; 183: Mulvey MR, Grant JM, Plewes K, Roscoe D, and Boyd DA. New Delhi metalloβ-lactamase in Klebsiella pneumoniae and Escherichia coli, Canada. Emerg Infect Dis 2011; 17: Ramirez MS & Tolmasky ME. Aminoglycoside modifying enzymes. Drug Resist Updat 2010; 13: Kumar A & Schweizer HP. Bacterial resistance to antibiotics: Active efflux and reduced uptake. Adv Drug Deliv Rev 2005, 57: Rodriguez-Martinez JM, Poirel L, Nordmann P. Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2009; 53: Doumith M, Ellington MJ, Livermore DM, et al. Molecular mechanisms disrupting porin expression in ertapenem-resistant Klebsiella and Enterobacter spp. clinical isolates from the UK. J Antimicrob Chemother 2009; 63: Pages J-M, James CE, Winterhalter M. The porin and the permeating antibiotic: A selective diffusion barrier in gram-negative bacteria. Nat Rev Microbiol 2008; 6: Poole K. Efflux-mediated antimicrobial resistance. J Antimicrob Chemother 2005; 56: Li, XZ & Nikaido H. Efflux-mediated drug resistance in bacteria: An update. Drugs 2009; 69: Perez F, Hujer AM, Hujer KM, et al. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2007, 51: Poole K & Srikumar R. Multidrug efflux in Pseudomonas aeruginosa: Components, mechanisms and clinical significance. Curr Top Med Chem 2001; 1: Lambert PA. Bacterial resistance to antibiotics: Modified target sites. Adv Drug Deliv Rev 2005; 57: Lowe FD. Antimicrobial resistance: The example of Staphylococcus aureus. J Clin Invest 2003; 111: Poole K. Resistance to β-lactam antibiotics. Cell Mol Life Sci 2004; 61: Grebe T & Hakenbeck R. Penicillin-binding proteins 2b and 2x of Streptococcus pneumoniae are primary resistance determinants for different classes of β-lactam antibiotics. Antimicrob Agents Chemother 1996; 40: Rybkine T, Mainardi JL, Sougakoff W, et al. Penicillin-binding protein 5 sequence alterations in clinical isolates of Enterococcus faecium with different levels of β-lactam resistance. J Infect Dis 1998; 178: Adam HJ, Schurek KN, Nichol KA, et al. Molecular characterization of increasing fluoroquinolone resistance in Streptococcus pneumoniae isolates in Canada, 1997 to Antimicrob Agents Chemother 2007; 51: Higgins PG, Fluit AC, Milatovic D, et al. Mutations in GyrA, ParC, MexR and NfxB in clinical isolates of Pseudomonas aeruginosa. Int J Antimicrob Agents 2003; 21: Morgan-Linnell SK, Boyd LB, Steffen D, et al. Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates. Antimicrob Agents Chemother 2009; 53: Wierzbowski AK, Nichol K, Laing N, et al. Macrolide resistance mechanisms among Streptococcus pneumoniae isolated over 6 years of Canadian Respiratory Organism Susceptibility Study (CROSS) ( ). J Antimicrob Chemother 2007; 60: Gold HS. Vancomycin-resistant enterococci: Mechanisms and clinical observations. Clin Infect Dis 2001; 33: French GL. Clinical impact and relevance of antibiotic resistance. Adv Drug Deliv Rev 2005; 57: Cosgrove SE. The relationship between antimicrobial resistance and patient outcomes: Mortality, length of hospital stay, and health care costs. Clin Infect Dis 2006; 42: S82-S Cosgrove SE, Sakoulas G, Perencevich EN, et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: A Meta-analysis. Clin Infect Dis 2003; 36: Linden PK, Pasculle AW, Manez R, et al. Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium. Clin Infect Dis 1996; 22: Tumbarello M, Spanu T, Sanguinetti M, et al. Bloodstream infections caused by extended-spectrum-β-lactamase-producing Klebsiella pneumoniae: Risk factors, molecular epidemiology, and clinical outcome. Antimicrob Agents Chemother 2006; 50: Tumbarello M, Spanu T, Di Bidino R, et al. Cost of bloodstream infections caused by Escherichia coli and influence of extended-spectrum-β-lactamase production and inadequate initial antibiotic therapy. Antimicrob Agents Chemother 2010; 54: Peralta G, Sanchez MB, Garrido JC, et al. Impact of antibiotic resistance and of adequate empirical antibiotic treatment in the prognosis of patients with Escherichia coli bacteraemia. J Antimicrob Chemother 2007; 60: Micek SC, Lloyd AE, Richie DJ, et al. Pseudomonas aeruginosa bloodstream infection: Importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother 2005; 49: Cosgrove SE & Carmeli Y. The impact of antimicrobial resistance on health and economic outcomes. Clin Infect Dis 2003; 36: Levin AS, Barone AA, Penco J, et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999; 28: Falagas ME & Kasaikou SK. Colistin: The revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections. Clin Infect Dis 2005; 40: Li J, Nation RL, Turnidge JD, et al. Colistin: the re-emerging antibiotic for multidrug-resistant gram-negative bacterial infections. Lancet Infect Dis 2006; 6: Spellberg B, Powers JH, Brass EP, et al. Trends in antimicrobial drug development: Implications for the future. Clin Infect Dis 2004; 38: Falagas ME & Bliziotis IA. Pandrug-resistant gram-negative bacteria: The dawn of the post-antibiotic era? Int J Antimicrob Agents 2007; 29: Livermore DM. Has the era of untreatable infections arrived? J Antimicrob Chemother 2009; 64: i29-i Canadian Committee on Antibiotic Resistance. Antimicrobial resistance: A deadly burden no country can afford to ignore. Can Commun Dis Rep 2003; 29: Canadian Expert Drug Advisory Committee. (2008). CEDAC final recommendation on reconsideration and reasons for recommendation Daptomycin. Retrieved January 18, 2011, from the World Wide Web: cdr/complete/cdr_complete_cubicin_%20september pdf. 62. World Health Organization. (2011). World Health Day 7 April 2011: Antimicrobial resistance and its global spread. Retrieved January 18, 2011, from the World Wide Web: Smith RD & Coast J. Antimicrobial resistance: A global response. Bull World Health Organ 2002; 80: Richman DD. Antiviral drug resistance. Antiviral drug resistance. Antiviral Res 2006; 71: Kanafani ZA & Perfect JR. Resistance to antifungal agents: Mechanisms and clinical impact. Clin Infect Dis 2008; 46: Borst P & Ouellette M. New mechanisms of drug resistance in parasitic protozoa. Annu Rev Microbiol 1995; 49:
5 62 Commentary Volume 8 No. 1, Geerts S & Gryseels B. Antihelmintic resistance in human helminths: A review. Trop Med Int Health 2001; 6: Dellit TH, Owens RC, McGowan JE, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America: Guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007; 44: Shlaes DM, Gerding DN, John Jr JF, et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: Guidelines for the prevention of antimicrobial resistance in hospitals. Infect Control Hosp Epidemiol 1997; 18: Norrby SR, Nord CE, Finch R. Lack of development of new antimicrobial drugs: A potential serious threat to public health. Lancet Infect Dis 2005; 5: Author Biography Justin D. Tilak is a first-year student at the Michael G. DeGroote School of Medicine, McMaster University. He received his Bachelor of Science degree at Queen s University.
Antimicrobial Cycling. Donald E Low University of Toronto
Antimicrobial Cycling Donald E Low University of Toronto Bad Bugs, No Drugs 1 The Antimicrobial Availability Task Force of the IDSA 1 identified as particularly problematic pathogens A. baumannii and
More informationConsequences of Antimicrobial Resistant Bacteria. Antimicrobial Resistance. Molecular Genetics of Antimicrobial Resistance. Topics to be Covered
Antimicrobial Resistance Consequences of Antimicrobial Resistant Bacteria Change in the approach to the administration of empiric antimicrobial therapy Increased number of hospitalizations Increased length
More informationMID 23. Antimicrobial Resistance. Consequences of Antimicrobial Resistant Bacteria. Molecular Genetics of Antimicrobial Resistance
Antimicrobial Resistance Molecular Genetics of Antimicrobial Resistance Micro evolutionary change - point mutations Beta-lactamase mutation extends spectrum of the enzyme rpob gene (RNA polymerase) mutation
More informationMechanism of antibiotic resistance
Mechanism of antibiotic resistance Dr.Siriwoot Sookkhee Ph.D (Biopharmaceutics) Department of Microbiology Faculty of Medicine, Chiang Mai University Antibiotic resistance Cross-resistance : resistance
More informationAntimicrobial Resistance
Antimicrobial Resistance Consequences of Antimicrobial Resistant Bacteria Change in the approach to the administration of empiric antimicrobial therapy Increased number of hospitalizations Increased length
More informationAntimicrobial Resistance Acquisition of Foreign DNA
Antimicrobial Resistance Acquisition of Foreign DNA Levy, Scientific American Horizontal gene transfer is common, even between Gram positive and negative bacteria Plasmid - transfer of single or multiple
More informationIntrinsic, implied and default resistance
Appendix A Intrinsic, implied and default resistance Magiorakos et al. [1] and CLSI [2] are our primary sources of information on intrinsic resistance. Sanford et al. [3] and Gilbert et al. [4] have been
More informationAntimicrobial Resistance
Antimicrobial Resistance Consequences of Antimicrobial Resistant Bacteria Change in the approach to the administration of Change in the approach to the administration of empiric antimicrobial therapy Increased
More informationBurton's Microbiology for the Health Sciences. Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents
Burton's Microbiology for the Health Sciences Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents Chapter 9 Outline Introduction Characteristics of an Ideal Antimicrobial Agent How
More informationSafe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times
Safe Patient Care Keeping our Residents Safe 2016 Use Standard Precautions for ALL Residents at ALL times #safepatientcare Do bugs need drugs? Dr Deirdre O Brien Consultant Microbiologist Mercy University
More informationMulti-drug resistant microorganisms
Multi-drug resistant microorganisms Arzu TOPELI Director of MICU Hacettepe University Faculty of Medicine, Ankara-Turkey Council Member of WFSICCM Deaths in the US declined by 220 per 100,000 with the
More informationNosocomial Infections: What Are the Unmet Needs
Nosocomial Infections: What Are the Unmet Needs Jean Chastre, MD Service de Réanimation Médicale Hôpital Pitié-Salpêtrière, AP-HP, Université Pierre et Marie Curie, Paris 6, France www.reamedpitie.com
More informationAntibiotic Resistance. Antibiotic Resistance: A Growing Concern. Antibiotic resistance is not new 3/21/2011
Antibiotic Resistance Antibiotic Resistance: A Growing Concern Judy Ptak RN MSN Infection Prevention Practitioner Dartmouth-Hitchcock Medical Center Lebanon, NH Occurs when a microorganism fails to respond
More informationMICRONAUT MICRONAUT-S Detection of Resistance Mechanisms. Innovation with Integrity BMD MIC
MICRONAUT Detection of Resistance Mechanisms Innovation with Integrity BMD MIC Automated and Customized Susceptibility Testing For detection of resistance mechanisms and specific resistances of clinical
More informationRecommendations for Implementation of Antimicrobial Stewardship Restrictive Interventions in Acute Hospitals in Ireland
Recommendations for Implementation of Antimicrobial Stewardship Restrictive Interventions in Acute Hospitals in Ireland A report by the Hospital Antimicrobial Stewardship Working Group, a subgroup of the
More informationRise of Resistance: From MRSA to CRE
Rise of Resistance: From MRSA to CRE Paul D. Holtom, MD Professor of Medicine and Orthopaedics USC Keck School of Medicine SUPERBUGS (AKA MDROs) MRSA Methicillin-resistant S. aureus Evolution of Drug Resistance
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More information2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine
2012 ANTIBIOGRAM Central Zone Former DTHR Sites Department of Pathology and Laboratory Medicine Medically Relevant Pathogens Based on Gram Morphology Gram-negative Bacilli Lactose Fermenters Non-lactose
More informationInfectious Disease: Drug Resistance Pattern in New Mexico
Infectious Disease: Drug Resistance Pattern in New Mexico Are these the world's sexiest accents? Obi C. Okoli, MD.,MPH. Clinic for Infectious Diseases Las Cruces, NM. Are these the world's sexiest accents?
More informationAntimicrobial Resistance Surveillance from sentinel public hospitals, South Africa, 2013
Antimicrobial Resistance Surveillance from sentinel public s, South Africa, 213 Authors: Olga Perovic 1,2, Melony Fortuin-de Smidt 1, and Verushka Chetty 1 1 National Institute for Communicable Diseases
More informationAntibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting
Antibiotic Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Any substance of natural, synthetic or semisynthetic origin which at low concentrations kills or inhibits the growth of bacteria
More informationOther Beta - lactam Antibiotics
Other Beta - lactam Antibiotics Assistant Professor Dr. Naza M. Ali Lec 5 8 Nov 2017 Lecture outlines Other beta lactam antibiotics Other inhibitors of cell wall synthesis Other beta-lactam Antibiotics
More informationWHY IS THIS IMPORTANT?
CHAPTER 20 ANTIBIOTIC RESISTANCE WHY IS THIS IMPORTANT? The most important problem associated with infectious disease today is the rapid development of resistance to antibiotics It will force us to change
More informationConcise Antibiogram Toolkit Background
Background This toolkit is designed to guide nursing homes in creating their own antibiograms, an important tool for guiding empiric antimicrobial therapy. Information about antibiograms and instructions
More informationEDUCATIONAL COMMENTARY - Methicillin-Resistant Staphylococcus aureus: An Update
EDUCATIONAL COMMENTARY - Methicillin-Resistant Staphylococcus aureus: An Update Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain
More information2016 Antibiotic Susceptibility Report
Fairview Northland Medical Center and Elk River, Milaca, Princeton and Zimmerman Clinics 2016 Antibiotic Susceptibility Report GRAM-NEGATIVE ORGANISMS 2016 Gram-Negative Non-Urine The number of isolates
More informationOriginal Articles. K A M S W Gunarathne 1, M Akbar 2, K Karunarathne 3, JRS de Silva 4. Sri Lanka Journal of Child Health, 2011; 40(4):
Original Articles Analysis of blood/tracheal culture results to assess common pathogens and pattern of antibiotic resistance at medical intensive care unit, Lady Ridgeway Hospital for Children K A M S
More information2015 Antibiotic Susceptibility Report
Citrobacter freundii Enterobacter aerogenes Enterobacter cloacae Escherichia coli Haemophilus influenzenza Klebsiella oxytoca Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa Serratia marcescens
More informationChallenges Emerging resistance Fewer new drugs MRSA and other resistant pathogens are major problems
Micro 301 Antimicrobial Drugs 11/7/12 Significance of antimicrobial drugs Challenges Emerging resistance Fewer new drugs MRSA and other resistant pathogens are major problems Definitions Antibiotic Selective
More informationRESISTANT PATHOGENS. John E. Mazuski, MD, PhD Professor of Surgery
RESISTANT PATHOGENS John E. Mazuski, MD, PhD Professor of Surgery Disclosures Contracted Research: AstraZeneca, Bayer, Merck. Advisory Boards/Consultant: Allergan (Actavis, Forest Laboratories), AstraZeneca,
More informationAntimicrobial Resistance and Prescribing
Antimicrobial Resistance and Prescribing John Ferguson, Microbiology & Infectious Diseases, John Hunter Hospital, University of Newcastle, NSW, Australia M Med Part 1 updates UPNG 2017 Tw @mdjkf http://idmic.net
More informationPrevalence of Metallo-Beta-Lactamase Producing Pseudomonas aeruginosa and its antibiogram in a tertiary care centre
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 4 Number 9 (2015) pp. 952-956 http://www.ijcmas.com Original Research Article Prevalence of Metallo-Beta-Lactamase
More informationANTIBIOTIC RESISTANCE. Syed Ziaur Rahman, MD, PhD D/O Pharmacology, JNMC, AMU, Aligarh
ANTIBIOTIC RESISTANCE Syed Ziaur Rahman, MD, PhD D/O Pharmacology, JNMC, AMU, Aligarh WHY IS THIS IMPORTANT? The most important problem associated with infectious disease today is the rapid development
More informationAntimicrobial Therapy
Antimicrobial Therapy David H. Spach, MD Professor of Medicine Division of Infectious Diseases University of Washington, Seattle Disclosure: Dr. Spach has no significant financial interest in any of the
More informationSummary of the latest data on antibiotic resistance in the European Union
Summary of the latest data on antibiotic resistance in the European Union EARS-Net surveillance data November 2017 For most bacteria reported to the European Antimicrobial Resistance Surveillance Network
More informationANTIBIOTICS USED FOR RESISTACE BACTERIA. 1. Vancomicin
ANTIBIOTICS USED FOR RESISTACE BACTERIA 1. Vancomicin Vancomycin is used to treat infections caused by bacteria. It belongs to the family of medicines called antibiotics. Vancomycin works by killing bacteria
More informationResistant Gram-negative Bacteria
Introduction Antibiotic-resistant bacteria aren t new. But gram-negative bacteria, like Enterobacteriaceae, are becoming more resistant to our last-line antibiotics. Some people are calling these bacteria
More informationSepsis is the most common cause of death in
ADDRESSING ANTIMICROBIAL RESISTANCE IN THE INTENSIVE CARE UNIT * John P. Quinn, MD ABSTRACT Two of the more common strategies for optimizing antimicrobial therapy in the intensive care unit (ICU) are antibiotic
More informationDR. MICHAEL A. BORG DIRECTOR OF INFECTION PREVENTION & CONTROL MATER DEI HOSPITAL - MALTA
DR. MICHAEL A. BORG DIRECTOR OF INFECTION PREVENTION & CONTROL MATER DEI HOSPITAL - MALTA The good old days The dread (of) infections that used to rage through the whole communities is muted Their retreat
More informationAntibiotics. Antimicrobial Drugs. Alexander Fleming 10/18/2017
Antibiotics Antimicrobial Drugs Chapter 20 BIO 220 Antibiotics are compounds produced by fungi or bacteria that inhibit or kill competing microbial species Antimicrobial drugs must display selective toxicity,
More informationInhibiting Microbial Growth in vivo. CLS 212: Medical Microbiology Zeina Alkudmani
Inhibiting Microbial Growth in vivo CLS 212: Medical Microbiology Zeina Alkudmani Chemotherapy Definitions The use of any chemical (drug) to treat any disease or condition. Chemotherapeutic Agent Any drug
More informationAntimicrobial Stewardship Strategy: Antibiograms
Antimicrobial Stewardship Strategy: Antibiograms A summary of the cumulative susceptibility of bacterial isolates to formulary antibiotics in a given institution or region. Its main functions are to guide
More informationRETROSPECTIVE STUDY OF GRAM NEGATIVE BACILLI ISOLATES AMONG DIFFERENT CLINICAL SAMPLES FROM A DIAGNOSTIC CENTER OF KANPUR
Original article RETROSPECTIVE STUDY OF GRAM NEGATIVE BACILLI ISOLATES AMONG DIFFERENT CLINICAL SAMPLES FROM A DIAGNOSTIC CENTER OF KANPUR R.Sujatha 1,Nidhi Pal 2, Deepak S 3 1. Professor & Head, Department
More informationIntroduction to Chemotherapeutic Agents. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The university of Jordan November 2018
Introduction to Chemotherapeutic Agents Munir Gharaibeh MD, PhD, MHPE School of Medicine, The university of Jordan November 2018 Antimicrobial Agents Substances that kill bacteria without harming the host.
More informationGENERAL NOTES: 2016 site of infection type of organism location of the patient
GENERAL NOTES: This is a summary of the antibiotic sensitivity profile of clinical isolates recovered at AIIMS Bhopal Hospital during the year 2016. However, for organisms in which < 30 isolates were recovered
More informationTable 1. Commonly encountered or important organisms and their usual antimicrobial susceptibilities.
Table 1. Commonly encountered or important organisms and their usual antimicrobial susceptibilities. Gram-positive cocci: Staphylococcus aureus: *Resistance to penicillin is almost universal. Resistance
More informationFighting MDR Pathogens in the ICU
Fighting MDR Pathogens in the ICU Dr. Murat Akova Hacettepe University School of Medicine, Department of Infectious Diseases, Ankara, Turkey 1 50.000 deaths each year in US and Europe due to antimicrobial
More informationAntibiotic resistance a mechanistic overview Neil Woodford
Antibiotic Resistance a Mechanistic verview BSc PhD FRCPath Consultant Clinical Scientist 1 Polymyxin Colistin Daptomycin Mechanisms of antibiotic action Quinolones Mupirocin Nitrofurans Nitroimidazoles
More informationSummary of the latest data on antibiotic consumption in the European Union
Summary of the latest data on antibiotic consumption in the European Union ESAC-Net surveillance data November 2016 Provision of reliable and comparable national antimicrobial consumption data is a prerequisite
More informationSelective toxicity. Antimicrobial Drugs. Alexander Fleming 10/17/2016
Selective toxicity Antimicrobial Drugs Chapter 20 BIO 220 Drugs must work inside the host and harm the infective pathogens, but not the host Antibiotics are compounds produced by fungi or bacteria that
More information2015 Antibiogram. Red Deer Regional Hospital. Central Zone. Alberta Health Services
2015 Antibiogram Red Deer Regional Hospital Central Zone Alberta Health Services Introduction. This antibiogram is a cumulative report of the antimicrobial susceptibility rates of common microbial pathogens
More informationAntimicrobial Susceptibility Patterns
Antimicrobial Susceptibility Patterns KNH SURGERY Department Masika M.M. Department of Medical Microbiology, UoN Medicines & Therapeutics Committee, KNH Outline Methodology Overall KNH data Surgery department
More informationMulti-drug resistant Acinetobacter (MDRA) Surveillance and Control. Alison Holmes
Multi-drug resistant Acinetobacter (MDRA) Surveillance and Control Alison Holmes The organism and it s epidemiology Surveillance Control What is it? What is it? What is it? What is it? Acinetobacter :
More informationHospital Acquired Infections in the Era of Antimicrobial Resistance
Hospital Acquired Infections in the Era of Antimicrobial Resistance Datuk Dr Christopher KC Lee Infectious Diseases Unit Department of Medicine Sungai Buloh Hospital Patient Story 23 Year old female admitted
More informationMike Apley Kansas State University
Mike Apley Kansas State University 2003 - Daptomycin cyclic lipopeptides 2000 - Linezolid - oxazolidinones 1985 Imipenem - carbapenems 1978 - Norfloxacin - fluoroquinolones 1970 Cephalexin - cephalosporins
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control as recommended by EUCAST Version 5.0, valid from 015-01-09 This document should be cited as "The
More information2017 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose
2017 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility
More information9/30/2016. Dr. Janell Mayer, Pharm.D., CGP, BCPS Dr. Lindsey Votaw, Pharm.D., CGP, BCPS
Dr. Janell Mayer, Pharm.D., CGP, BCPS Dr. Lindsey Votaw, Pharm.D., CGP, BCPS 1 2 Untoward Effects of Antibiotics Antibiotic resistance Adverse drug events (ADEs) Hypersensitivity/allergy Drug side effects
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXIII NUMBER 1 July 2008 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell, SM (ASCP), Marti Roe SM (ASCP), Ann-Christine Nyquist MD, MSPH Are the bugs winning? The 2007
More informationDoes Screening for MRSA Colonization Have A Role In Healthcare-Associated Infection Prevention Programs?
Does Screening for MRSA Colonization Have A Role In Healthcare-Associated Infection Prevention Programs? John A. Jernigan, MD, MS Division of Healthcare Quality Promotion Centers for Disease Control and
More informationAntimicrobial stewardship: Quick, don t just do something! Stand there!
Antimicrobial stewardship: Quick, don t just do something! Stand there! Stanley I. Martin, MD, FACP, FIDSA Director, Division of Infectious Diseases Director, Antimicrobial Stewardship Program Geisinger
More informationWhy should we care about multi-resistant bacteria? Clinical impact and
Why should we care about multi-resistant bacteria? Clinical impact and public health implications Prof. Stephan Harbarth Infection Control Program Geneva, Switzerland and Ebola (in 2014/2015) Increased
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control for MIC determination and disk diffusion as recommended by EUCAST Version 8.0, valid from 018-01-01
More informationEducating Clinical and Public Health Laboratories About Antimicrobial Resistance Challenges
Educating Clinical and Public Health Laboratories About Antimicrobial Resistance Challenges Janet Hindler, MCLS MT(ASCP) UCLA Medical Center jhindler@ucla.edu also working as a consultant with the Association
More informationReport on the APUA Educational Symposium: "Facing the Next Pandemic of Pan-resistant Gram-negative Bacilli"
Preserving the Power of Antibiotics Report on the APUA Educational Symposium: "Facing the Next Pandemic of Pan-resistant Gram-negative Bacilli" Held on Thursday, September 30, 2004 in Boston, MA Preceding
More informationChemotherapy of bacterial infections. Part II. Mechanisms of Resistance. evolution of antimicrobial resistance
Chemotherapy of bacterial infections. Part II. Mechanisms of Resistance evolution of antimicrobial resistance Mechanism of bacterial genetic variability Point mutations may occur in a nucleotide base pair,
More informationAntimicrobial Susceptibility Testing: Advanced Course
Antimicrobial Susceptibility Testing: Advanced Course Cascade Reporting Cascade Reporting I. Selecting Antimicrobial Agents for Testing and Reporting Selection of the most appropriate antimicrobials to
More information5/4/2018. Multidrug Resistant Organisms (MDROs) Objectives. Outline. Define a multi-drug resistant organism (MDRO)
Multidrug Resistant Organisms (MDROs) Kasturi Shrestha, M.D. 05/11/2018 Objectives Define a multi-drug resistant organism (MDRO) Identify most challenging MDROs in healthcare Identify reasons for health
More informationGUIDE TO INFECTION CONTROL IN THE HOSPITAL. Antibiotic Resistance
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER 4: Antibiotic Resistance Author M.P. Stevens, MD, MPH S. Mehtar, MD R.P. Wenzel, MD, MSc Chapter Editor Michelle Doll, MD, MPH Topic Outline Key Issues
More informationTestimony of the Natural Resources Defense Council on Senate Bill 785
Testimony of the Natural Resources Defense Council on Senate Bill 785 Senate Committee on Healthcare March 16, 2017 Position: Support with -1 amendments I thank you for the opportunity to address the senate
More informationJanuary 2014 Vol. 34 No. 1
January 2014 Vol. 34 No. 1. and Minimum Inhibitory Concentration (MIC) Interpretive Standards for Testing Conditions Medium: diffusion: Mueller-Hinton agar (MHA) Broth dilution: cation-adjusted Mueller-Hinton
More informationnumber Done by Corrected by Doctor Dr Hamed Al-Zoubi
number 8 Done by Corrected by Doctor Dr Hamed Al-Zoubi 25 10/10/2017 Antibacterial therapy 2 د. حامد الزعبي Dr Hamed Al-Zoubi Antibacterial therapy Figure 2/ Antibiotics target Inhibition of microbial
More informationMercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016
Mercy Medical Center Des Moines, Iowa Department of Pathology Microbiology Department Antibiotic Susceptibility January December 2016 These statistics are intended solely as a GUIDE to choosing appropriate
More information2016 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose
2016 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility
More information56 Clinical and Laboratory Standards Institute. All rights reserved.
Table 2C 56 Clinical and Laboratory Standards Institute. All rights reserved. Table 2C. Zone Diameter and Minimal Inhibitory Concentration Breakpoints for Testing Conditions Medium: Inoculum: diffusion:
More informationThe emergence of antibiotic-resistant organisms is a
CMAJ Antimicrobial resistance in hospitals: How concerned should we be? Michael R. Mulvey PhD, Andrew E. Simor MD @@ See related commentary by Nicolle and colleagues, page 371, and related analysis paper
More informationجداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی
جداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی ویرایش دوم بر اساس ed., 2017 CLSI M100 27 th تابستان ۶۹۳۱ تهیه
More information03/09/2014. Infection Prevention and Control A Foundation Course. Talk outline
Infection Prevention and Control A Foundation Course 2014 What is healthcare-associated infection (HCAI), antimicrobial resistance (AMR) and multi-drug resistant organisms (MDROs)? Why we should be worried?
More informationFlorida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC
Florida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC 11/20/2014 1 To describe carbapenem-resistant Enterobacteriaceae. To identify laboratory detection standards for carbapenem-resistant
More informationNational Clinical Guideline Centre Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults
National Clinical Guideline Centre Antibiotic classifications Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults Clinical guideline 191 Appendix N 3 December 2014
More informationSuggestions for appropriate agents to include in routine antimicrobial susceptibility testing
Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing These suggestions are intended to indicate minimum sets of agents to test routinely in a diagnostic laboratory
More informationImagine. Multi-Drug Resistant Superbugs- What s the Big Deal? A World. Without Antibiotics. Where Simple Infections can be Life Threatening
Multi-Drug Resistant Superbugs- What s the Big Deal? Toni Biasi, RN MSN MPH CIC Infection Prevention Indiana University Health Imagine A World Without Antibiotics A World Where Simple Infections can be
More informationEUCAST recommended strains for internal quality control
EUCAST recommended strains for internal quality control Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus influenzae ATCC 59 ATCC
More informationInt.J.Curr.Microbiol.App.Sci (2017) 6(3):
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 3 (2017) pp. 891-895 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.603.104
More informationMedicinal Chemistry 561P. 2 st hour Examination. May 6, 2013 NAME: KEY. Good Luck!
Medicinal Chemistry 561P 2 st hour Examination May 6, 2013 NAME: KEY Good Luck! 2 MDCH 561P Exam 2 May 6, 2013 Name: KEY Grade: Fill in your scantron with the best choice for the questions below: 1. Which
More informationWhat does multiresistance actually mean? Yohei Doi, MD, PhD University of Pittsburgh
What does multiresistance actually mean? Yohei Doi, MD, PhD University of Pittsburgh Disclosures Merck Research grant Clinical context of multiresistance Resistance to more classes of agents Less options
More informationANTIBIOTICS: TECHNOLOGIES AND GLOBAL MARKETS
ANTIBIOTICS: TECHNOLOGIES AND GLOBAL MARKETS PHM025D March 2016 Neha Maliwal Project Analyst ISBN: 1-62296-252-4 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free
More informationAntibiotics: mode of action and mechanisms of resistance. Slides made by Special consultant Henrik Hasman Statens Serum Institut
Antibiotics: mode of action and mechanisms of resistance. Slides made by Special consultant Henrik Hasman Statens Serum Institut This presentation Definitions needed to discuss antimicrobial resistance
More informationDoripenem: A new carbapenem antibiotic a review of comparative antimicrobial and bactericidal activities
REVIEW Doripenem: A new carbapenem antibiotic a review of comparative antimicrobial and bactericidal activities Fiona Walsh Department of Clinical Microbiology, Trinity College Dublin, Dublin, Ireland
More informationBACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016)
BACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016) VA Palo Alto Health Care System April 14, 2017 Trisha Nakasone, PharmD, Pharmacy Service Russell Ryono, PharmD, Public Health Surveillance
More informationAberdeen Hospital. Antibiotic Susceptibility Patterns For Commonly Isolated Organisms For 2015
Aberdeen Hospital Antibiotic Susceptibility Patterns For Commonly Isolated s For 2015 Services Laboratory Microbiology Department Aberdeen Hospital Nova Scotia Health Authority 835 East River Road New
More informationEinheit für pädiatrische Infektiologie Antibiotics - what, why, when and how?
Einheit für pädiatrische Infektiologie Antibiotics - what, why, when and how? Andrea Duppenthaler andrea.duppenthaler@insel.ch Limping patient local pain swelling tenderness warmth fever acute Osteomyelitis
More informationUpdate on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia. Po-Ren Hsueh. National Taiwan University Hospital
Update on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia Po-Ren Hsueh National Taiwan University Hospital Ventilator-associated Pneumonia Microbiological Report Sputum from a
More informationANTIMICROBIAL RESISTANCE SURVEILLANCE FROM SENTINEL PUBLIC HOSPITALS, SOUTH AFRICA, 2014
ANTIMICROBIAL RESISTANCE SURVEILLANCE FROM SENTINEL PUBLIC HOSPITALS, SOUTH AFRICA, 2014 Olga Perovic, 1,2 Verushka Chetty 1 & Samantha Iyaloo 1 1 National Institute for Communicable Diseases, NHLS 2 Department
More informationLack of Change in Susceptibility of Pseudomonas aeruginosa in a Pediatric Hospital Despite Marked Changes in Antibiotic Utilization
Infect Dis Ther (2014) 3:55 59 DOI 10.1007/s40121-014-0028-8 BRIEF REPORT Lack of Change in Susceptibility of Pseudomonas aeruginosa in a Pediatric Hospital Despite Marked Changes in Antibiotic Utilization
More informationChildrens Hospital Antibiogram for 2012 (Based on data from 2011)
Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Prepared by: Department of Clinical Microbiology, Health Sciences Centre For further information contact: Andrew Walkty, MD, FRCPC Medical
More informationThe β- Lactam Antibiotics. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018
The β- Lactam Antibiotics Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018 Penicillins. Cephalosporins. Carbapenems. Monobactams. The β- Lactam Antibiotics 2 3 How
More informationNew Drugs for Bad Bugs- Statewide Antibiogram
New Drugs for Bad Bugs- Statewide Antibiogram Felicia Matthews, Pharm.D., BCPS Senior Consultant, Pharmacy Specialty BE MedMined Services Disclosures Employee of BD Corporation MedMined Services Agenda
More informationFluoroquinolones in 2007: the Angels, the Devils, and What Should the Clinician Do?
Fluoroquinolones in 2007: the Angels, the Devils, and What Should the Clinician Do? David C. Hooper, M.D. Division of Infectious Diseases Infection Control Unit Massachusetts General Hospital Harvard Medical
More informationRoutine internal quality control as recommended by EUCAST Version 3.1, valid from
Routine internal quality control as recommended by EUCAST Version.1, valid from 01-01-01 Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus
More information